Natural product, Dihydro-resveratrol for treating colorectal cancer and melanoma


According to World Health Organization (WHO), colorectal cancer is the 3rd most common cancer and the 2nd leading cause of cancer death worldwide, accounting for about one in ten cancer cases and deaths.


The drug 5-Fluorouracil (5-FU) has been the first choice to treat colorectal cancer for years.

In addition to the common side effects of chemotherapy, the usage of 5-FU may also lead to increased risk of infection, easy bruising and bleeding, and anaemia. In light of its high cytotoxicity and low bioavailability, there is a need to develop other anti-cancer drugs with less side effects.


Our technology is related to the usage of a bioactive compound dihydro-resveratrol (D-res) or its stilbenoid derivatives. They are drug-like small molecules derived from herbal constituents and can be used as chemotherapeutic agents for treating tumours or cancers.




Dihydro-resveratrol (D-res) can be found in wine and it belongs to a class of natural products (polyphenolic stilbenoids) with bioactivities.


In our experiments, it is demonstrated that D-res could provide significant therapeutic effect on colorectal cancer without adverse effects through our observation. The therapeutic effect of this anti-cancer agent is comparable with that of 5-FU, but with a much lower toxicity.


Therefore, the D-res is an experimentally proven antitumor agent that can be prescribed safely to cancer patients even at much higher doses than 5-FU. In our toxicity study, the D-res shows no toxicity even at very high dose of 6000 mg/kg.


In addition, D-res and its stilbenoid derivatives can be synthesized from Resveratrol, which is found naturally in many plants. They can be developed as food dietary compounds for treating or preventing cancers.



D-res or its stilbenoid derivatives can be used in treating several types of cancers including colorectal cancer and melanoma. It is safe to use even at a high dose.

Besides, they can be developed as food dietary compounds for treating or preventing cancers.



Colorectal cancer is the 3rd most common cancer globally and is one of the most common causes of cancer deaths in the world. The global colorectal cancer therapeutics market can increase from $13.7 billion to $18.5 billion at a compound annual growth rate (CAGR) of 6.1% during the period 2018 to 2023.



Patients can benefit from a new and safe anti-cancer drug with lower toxicity than 5-FU. Undesirable side effects can be minimized too.

Healthcare - Pharmaceuticals & Therapeutics
Technology Status

Available for Licensing

Technology Readiness Level

Anticancer, Antitumor, Colon cancer, Melanoma, Pancreatic cancer

Published on
Jan 18, 2022
Updated on
Jan 18, 2022
Make an Enquiry